Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-TR2205
- Development stage
- Unknown
- Lead developer
- Tongrui Biopharmaceutical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-TR2205 is an investigational radiopharmaceutical diagnostic agent developed by Tongrui Biopharmaceutical (Chengdu) Co., Ltd. for the detection and localization of recurrent metastatic prostate cancer. It consists of the positron-emitting radioisotope Copper-64 (64Cu) conjugated to TR2205, a high-affinity ligand targeting Prostate-Specific Membrane Antigen (PSMA). PSMA is a cell-surface protein that is significantly overexpressed in nearly all prostate cancer cells, with levels increasing in higher-grade, metastatic, and castration-resistant disease. Upon intravenous administration, 64Cu-TR2205 binds to PSMA-expressing cells, allowing for high-resolution Positron Emission Tomography (PET) imaging. The use of Copper-64 provides a longer physical half-life (12.7 hours) compared to Gallium-68 (68 minutes), which facilitates delayed imaging to improve tumor-to-background ratios and enables centralized production and distribution to clinical centers without on-site cyclotrons.
- Other names
- Copper-64 TR2205Copper64 TR2205Copper 64 TR2205
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 64Cu-TR2205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-TR2205.